Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$4.75B
sum of reported positions
Reported positions
148
Changes vs prior quarter
142
17 new · 24 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 105 measured positions in 8 quarters, the typical new or larger position finished +0.6 pts against the S&P 500 and 52% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 852K | $308M | 6.5% | |
| 579K | $287M | 6.0% | |
| 301K | $279M | 5.9% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $4.2B | $4.75B |
| Positions | 155 | 148 |
| Biggest line | — | Amgen 6% |
| 2.16M |
| $273M |
| 5.7% |
| 1.05M | $196M | 4.1% |
| 1.66M | $158M | 3.3% |
| 1.39M | $149M | 3.1% |
| 2.45M | $135M | 2.8% |
NUVALENT INC | 1.05M | $130M | 2.7% |
| 6.73M | $124M | 2.6% |
| 6.19M | $116M | 2.4% |
| 1.97M | $115M | 2.4% |
| 189K | $102M | 2.1% |
| 255K | $101M | 2.1% |
| 157K | $98.1M | 2.1% |
CRINETICS PHARMACEUTICALS IN | 2.62M | $98M | 2.1% |
| 1.19M | $88.6M | 1.9% |
| 2.79M | $88.5M | 1.9% |
| 947K | $85.9M | 1.8% |
| 268K | $84.5M | 1.8% |
| 994K | $77.8M | 1.6% |
| 972K | $77.1M | 1.6% |
| 1.49M | $75.6M | 1.6% |
| 1.71M | $73.4M | 1.5% |
| 3.06M | $67.9M | 1.4% |
Amgen (AMGN)
295K → 852K shares (+188%)
Vertex Pharmaceuticals (VRTX)
682K → 579K shares (−15%)
Argenx (ARGX)
313K → 301K shares (−4%)
Gilead Sciences (GILD)
1.17M → 2.16M shares (+85%)
Revolution Medicines (RVMD)
1.54M → 1.05M shares (−32%)
Oruka Therapeutics (ORKA)
507K → 1.66M shares (+227%)
Insmed (INSM)
10K → 1.39M shares (+13787%)
Scholar Rock Holding (SRRK)
3.58M → 2.45M shares (−32%)
Relay Therapeutics (RLAY)
7.8M → 6.19M shares (−21%)
Vaxcyte (PCVX)
1.19M → 1.97M shares (+66%)
United Therapeutics (UTHR)
2,077 → 189K shares (+8976%)
Intuitive Surgical (ISRG)
287K → 255K shares (−11%)
Regeneron Pharmaceuticals (REGN)
279K → 157K shares (−44%)
CRINETICS PHARMACEUTICALS IN
3.28M → 2.62M shares (−20%)
Bridgebio Pharma (BBIO)
25K → 1.19M shares (+4587%)
Abbott Laboratories (ABT)
1.15M → 947K shares (−18%)
Stryker Corporation (SYK)
217K → 268K shares (+24%)
Medtronic (MDT)
957K → 994K shares (+4%)
Ionis Pharmaceuticals (IONS)
1.82M → 972K shares (−47%)
Enliven Therapeutics (ELVN)
2.32M → 1.49M shares (−36%)
Jade Biosciences (JBIO)
3.5M → 3.06M shares (−13%)
Edwards Lifesciences (EW)
839K → 739K shares (−12%)
Ultragenyx Pharmaceutical (RARE)
2.38M → 1.98M shares (−17%)
Dexcom (DXCM)
789K → 822K shares (+4%)
Avalyn Pharma (AVLN)
1.35M shares
